June: Micera


Mircera® in Dialysis – a US Experience
June 30, 2021
1:00 PM ET

Since December 2014, Mircera® (methoxy polyethylene glycol-epoetin beta) injection, for intravenous or subcutaneous use, has been available in the United States. Initially, available exclusively via FKC dialysis clinics, as of late 2017, Mircera® was introduced by other dialysis providers as well. Expanded use of Mircera® in recent years has allowed many US dialysis providers to gain valuable first-hand experience with this long-acting ESA, some of which has been described and shared in recent publications. Presenters will share general information, key findings, and published conclusions based on the Mircera® US experience.


* Non-Renal Healthcare Association Members have access to Education Station (online courses,) but may pay a higher fee per course and are required to register as a Webinar Attendee first. Webinar Attendees do not receive member pricing for courses or any other Member Benefits.


Sponsored by:

Presented by 

Chance Mysayphonh, PharmD
Corporate Clinical Pharmacist, Global Clinical Affairs, Fresenius Kidney Care

Dr. Chance Mysayphonh serves as Director of Clinical Pharmacy Initiatives for Fresenius Medical Care, overseeing the Antibiotic Stewardship Program and clinical pharmacy initiatives for FMC North America. Dr. Mysayphonh received his Doctor of Pharmacy from The University of Tennessee with graduate training from Vanderbilt University. Prior to Fresenius, he served as Clinical Systems Analyst for TwelveStone Health Partners where he supported multiple clinical teams by utilizing data to improve outcomes and led the Accreditation and Certification Committee. Dr. Mysayphonh also served as Clinical Infusion Pharmacist for Vanderbilt HC/Walgreens Infusion, where he provided post-acute care to prevent rehospitalization, led the clinical team for all chemotherapy patients, and worked closely with the Vanderbilt Infectious Disease Clinic regarding antibiotic drug protocols and therapy management.

Tomislav Kovacevic, MD
Medical Lead ESA, Vifor Pharma Group

Dr. Kovacevic is currently employed by Vifor Pharma as Medical Lead for erythropoiesis-stimulating agents (ESAs) and responsible for all medical-related activities associated with Vifor’s ESA portfolio. Dr. Kovacevic received his medical degree at the University of Zagreb Medical School, Croatia, in Europe. He has been working in the pharmaceutical industry for the last 17 years, leading both local and international cross-functional teams. Tomislav joined Vifor in 2015, and has since focused on anemia associated with CKD, both from the perspective of iron deficiency as well as ESA management.